Status:

UNKNOWN

The Effect of Platelet-Rich Plasma-Fibrin Glue in Combination With Vitamin E and C for Treatment of Non-healing Diabetic Foot Ulcers

Lead Sponsor:

Mashhad University of Medical Sciences

Conditions:

Diabetic Foot Ulcers

Diabetic Wound

Eligibility:

All Genders

35-75 years

Phase:

PHASE2

PHASE3

Brief Summary

The aim of this study is to evaluates the chance of non-healing Diabetic Foot Ulcers repair by reducing oxidative stress caused by diabetes by taking vitamin E and C supplements along with the use of ...

Eligibility Criteria

Inclusion

  • DFU is classified as Wagner 1 -2 on the Wagner classification system.
  • Persons with type 1 or type 2 diabetes with a non-healing ulcer of at least 4 weeks duration.
  • If more than one non-healing wound is present, the largest of the wounds that is classified as a Wagner 1- 2.
  • The index ulcer had to be clinically non-infected.
  • Ankle Brachial Index (ABI) greater than or equal to 0.7.
  • HemoglobinA1C (HbA1c) \< 12
  • Index foot ulcer located on the plantar, medial, or lateral aspect of the foot (including all toe surfaces).
  • Wound area (length x width) measurement between 2 cm2 and 20 cm2.
  • Non-use of drugs that may interfere with wound healing, such as corticosteroids, immunosuppressive agents, and cytotoxic agents.
  • No smoking, alcohol or drug addiction.
  • Approved, informed, signed consent.

Exclusion

  • Previous consumption of vitamin E and C supplements.
  • Index ulcer has exposed tendons, ligaments, muscle, or bone.
  • Confirmed presence of osteomyelitis, or if osteomyelitis is suspected.
  • Patients with renal deficiency, hepatic failure, has known immune insufficiency and cancer.
  • Subject is pregnant or plans to become pregnant during the duration of the trial.
  • Patient's blood vessels are non-compressible for ABI testing.
  • Patient is known to have a psychological, developmental, physical, emotional disorders.
  • Received systemic corticosteroids or immunosuppressive agents.

Key Trial Info

Start Date :

August 28 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 23 2020

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT04315909

Start Date

August 28 2019

End Date

June 23 2020

Last Update

March 20 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Alavi Hospital

Mashhad, Razavi Khorasan Province, Iran, 9137913316